Rationale Several studies implicate stress as a risk factor for the development and maintenance of drug addictive behaviors and drug relapse. Kappa opioid receptor (KOR) antagonists have been shown to attenuate behavioral responses to stress and stress-induced reinstatement of cocaine and ethanol seeking and preference. Objectives In the current study, we determined whether the selective KOR antagonist, norbinaltorphimine (nor-BNI), would block stress-induced reinstatement of nicotine preference. Methods Adult Institute of Cancer Research mice were conditioned with 0.5 mg/kg nicotine, injected subcutaneously (s.c.) for 3 days and tested in the nicotine-conditioned place preference (CPP) model. After 3 days extinction, nor-BNI (10 mg/kg, s.c.) was administered 16 h prior to a priming dose of nicotine (0.1 mg/kg, s.c.), and mice were tested in the CPP model for nicotine-induced reinstatement of CPP. A separate group of mice was subjected to a 2-day modified forced swim test (FST) paradigm to induce stress after 3 days extinction from CPP. Mice were given vehicle or nor-BNI (10 mg/kg, s.c.) 16 h prior to each FST session. Results Nor-BNI pretreatment significantly attenuated stress-induced reinstatement of nicotine-CPP, but had no effect on nicotine-primed reinstatement. Conclusions Blockade of KORs by selective antagonists attenuates stress-induced reinstatement of nicotine-CPP. Overall, the kappa opioid system may serve as a therapeutic target for suppressing multiple signaling processes which contribute to maintenance of smoking, smoking relapse, and drug abuse in general.
Introduction
Stress is implicated as a risk factor in the development and maintenance of drug addictive behaviors and relapse to drug abuse. Indeed, exposure to stressors in humans has been shown to increase cigarette puff rate, volume of smoke inhaled (Rose et al. 1983 ), smoking and nicotine intake (Pomerleau and Pomerleau 1987; Todd 2004) , and desire to smoke (Perkins and Grobe 1992; Todd 2004) . Similarly, exposure to stressors is a predictor for relapse to cocaine (McMahon 2001) , and the exaggerated stress response often observed in former opiate and cocaine abusers has been linked to drug relapse (Kreek 1987) . Stressful situations also increase alcohol intake in humans (Pohorecky 1981) . In support of these findings, animal studies report enhanced drug-induced reinstatement of cocaine self-administration (Beardsley et al. 2005) , enhanced cocaine reward (McLaughlin et al. 2003) , and enhanced ethanol reward and ethanol intake in the two-bottle choice paradigm (Sperling et al. 2010 ) after exposure to stressors.
One mechanism for this enhanced response to drugs of abuse following stressors involves kappa opioid receptor (KOR) pathways. Dynorphin, the endogenous KOR ligand, is released in response to stress, activating the kappa opioid system and mediating behavioral responses to stressors (see Bruchas et al. 2010 for review). A study by McLaughlin et al. (2003) reported that the selective KOR antagonist, norbinaltorphimine (nor-BNI), blocks stressed-induced analgesia, reduces stress-induced immobility in the forced swim test (FST), and blocks stress-induced potentiation of cocaine-conditioned place preference (CPP) in mice. Similar blockade of stress-induced analgesia and potentiation of cocaine-CPP was also observed with the selective KOR antagonist arodyn, a novel peptide ligand based on the structure of dynorphin A (Carey et al. 2007 ). In addition to the FST, nor-BNI attenuated enhanced cocaine reinstatement of CPP from stress induced by footshock in mice (Redila and Chavkin 2008) . Nor-BNI also significantly blocked stress-induced enhancement of ethanol consumption and reward in mice (Sperling et al. 2010) . Consistent with these results, mice null for the prodynorphin gene, the precursor protein for dynorphin, did not show stressinduced enhancement of cocaine-CPP (McLaughlin et al. 2003; Redila and Chavkin 2008) or ethanol consumption (Sperling et al. 2010) . Additionally, nor-BNI and (3R)-7-hydroxy-N-[(1 S)-1-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-di methyl-1-piperidinyl]methyl]-2-methylpropyl]-1,2,3,4-tet rahydro-3-isoquinoline-carboxamide (JDTic), a potent, selective KOR antagonist, decreased immobility in the FST and reduced the ability of a footshock stressor to reinstate cocaine self-administration in rats (Beardsley et al. 2005) . Despite these studies indicating an apparent role for KORs in stress-induced relapse of cocaine and ethanol, to date, it is unclear if this blockade extends to nicotine. Nicotine is known to affect stress pathways, inducing alterations in the corticotrophin-releasing factor, hypothalamic-pituitaryadrenal axis, and autonomic nervous system pathways, and changes in heart rate and blood pressure (Wilkins et al. 1982; Cinciripini et al. 1989; Mendelson et al. 2005; Chen et al. 2008) . Such nicotine-induced alterations to stress and dopamine pathways contribute to the negative affect, craving, and increased relapse susceptibility associated with nicotine withdrawal (Sinha 2008; Renthal and Nestler 2008) . Indeed, a major issue in smoking cessation is the high rate of relapse, which, after 1 year of initial treatment, is approximately 75 % (Gonzales et al. 2006) .
We therefore extended the studies to nicotine and tested whether the selective KOR antagonist, nor-BNI, would block stress-induced reinstatement of nicotine-CPP, using the modified FST to induce stress in mice. To test if the effect was specific to stress-induced reinstatement, we also assessed the ability of nor-BNI to block nicotine-primed reinstatement of nicotine-CPP.
Methods

Animals
Male Institute for Cancer Research mice, purchased from Jackson Laboratories (Bar Harbor, ME), were housed in a 21°C humidity-controlled Association for Assessment and Accreditation of Laboratory Animal Care-approved animal care facility with food and water available ad libitum. The rooms were on a 12-h light/dark cycle (lights on at 7:00A.M.). Nicotine-CPP An unbiased CPP paradigm was utilized in this study as described in Kota et al (2007) . Briefly, place-conditioning chambers consisted of two distinct compartments separated by a smaller intermediate compartment with openings that allowed access to either side of the chamber. On day 1, animals were confined to the intermediate compartment for a 5-min habituation period and then allowed to move freely between compartments for 15 min. Time spent in each compartment was recorded. These data were used to separate the animals into groups of approximately equal bias. Days 2-4 were the conditioning days during which the saline group received saline in both compartments, and drug groups received nicotine (0.5 mg/kg, s.c.) in one compartment and saline in the opposite compartment. Drug-paired compartments were randomized among all groups. Day 5 was the drug-free test day, and the procedure was the same as day 1. Activity counts and time spent on each side were recorded via photosensors using Med Associates interface and software. Data were expressed as time spent on the drug-paired side postconditioning minus time spent on the drug-paired side preconditioning. A positive number indicated a preference for the drug-paired side, whereas a negative number indicated an aversion to the drug-paired side. A number at or near zero indicated no preference for either side.
Nicotine-primed reinstatement of nicotine-CPP Two individual cohorts of seven to nine mice were tested in the CPP paradigm and classified into groups A and B. On day 6, 1 day after test day, the test day procedure was repeated in both groups for three additional days to measure extinction of nicotine-CPP. All mice received saline injections (s.c.) prior to entering the chambers on these days. After day 8 test session, group A mice received an injection of nor-BNI (10 mg/kg, s.c.), and group B mice received an injection of vehicle, 16 h prior to day 9 test session. On day 9, mice received an injection of nicotine (0.1 mg/kg, s.c.), and a subset of animals from group A, the nor-BNI pretreated group (n04 for saline and nicotine) received vehicle, and were immediately placed in the chamber for testing. A timeline for the experiment is shown in Fig. 1a .
Stress-induced reinstatement of nicotine-CPP As in the nicotine-primed reinstatement study, two individual cohorts of six to eight mice, groups A and B, were tested in the CPP paradigm. After three CPP extinction days (day 8), nicotine-conditioned mice from group B received injections of nor-BNI (10 mg/kg, s.c.), while nicotine-conditioned mice from group A received vehicle. Saline-conditioned mice served as a control group (unstressed) and were treated with vehicle (group A) or nor-BNI (group B) in the home cage, according to the same treatment schedule as mice subjected to the FST. On day 9, 16 h after nor-BNI pretreatment, to induce stress, mice were exposed to a 2-day modified forced swim test (Porsolt et al. 1977; McLaughlin et al. 2003) . Briefly, mice swam in opaque 5-l beakers filled with 3.5 l of 30°C water. After each trial, the mice were dried with towels and returned to their home cages before further testing. On day 1 of the FST (experiment day 9), mice were placed in water to swim for a single trial of 15 min. At the end of FST day 1, mice were again pretreated with nor-BNI or vehicle 16 h prior to FST day 2. On day 2 of the FST (experiment day 10), mice were placed in water to swim through a series of four trials, each 6 min long. Trials were separated by a 10-min return to the home cage. Difficulties in swimming or staying afloat were the criteria for exclusion in this study; however, no mice met these criteria. On day 11, mice were reexposed to the CPP chambers for testing. A timeline for the experiment is shown in Fig. 1b .
Statistical analysis
Statistical analyses for both studies were conducted using repeated measures analysis of variance testing with between-subjects factors. All comparisons were between cohorts (groups A and B), test day, postconditioning days, and treatment (saline vs. nicotine). Values of p<0.05 were considered to be statistically significant. Significant results were further assessed using Neuman-Keuls post-hoc analysis.
Results
Effects of nor-BNI on nicotine-primed reinstatement of nicotine-CPP
A significant between-subjects main effect revealed a robust CPP established in mice in response to nicotine (0.5 mg/kg, s.c.) in both cohorts (F (1,80) 031.12, p<0.0001; Fig. 2 ). After 1 day extinction from CPP, nicotine preference was still expressed; however, this effect was extinguished after 3 days extinction from nicotine-CPP, as supported by a significant within-subject×between-subject interaction (F (5,80) 05.69, p<0.01). At a dose of 0.1 mg/kg nicotine, CPP was reinstated in vehicle pretreated mice (Fig. 2) . Nicotine-primed reinstatement of CPP was not blocked by pretreatment with Fig. 1 Timelines for nicotine-CPP reinstatement studies. a Timeline for the nicotineprimed nicotine-CPP reinstatement and b stress-induced nicotine-CPP reinstatement study nor-BNI (10 mg/kg, s.c.), administered 16 h prior to test day, as these mice also exhibited a significant reinstatement of nicotine-CPP. There were no significant differences between cohorts on any days tested. Nor-BNI alone had no significant effect on reinstatement of nicotine-CPP at the dose tested. CPP locomotor activity counts did not significantly differ between postconditioning reinstatement groups (Veh/ Nic 0516.8 ± 32.8; nor-BNI/Veh 0473.3 ± 61.4; nor-BNI/ Nic0496.7±83.3).
Effects of nor-BNI on stress-induced reinstatement of nicotine-CPP
A robust nicotine-CPP was observed in both cohorts on test day (F (1,54) 078.61, p<0.0001; Fig. 3 ). Following three CPP extinction days, stress was induced in nicotine-conditioned mice using a 2-day modified FST. Mice were pretreated with vehicle or nor-BNI (10 mg/kg, s.c.) 16 h before each FST session. Saline-conditioned mice received the same treatment in the home cages, but were not subjected to the FST (unstressed). The FST reinstated nicotine-CPP in vehicle pretreated mice (F (3,54) 010.09, p<0.01; Fig. 3 ). Alternatively, stress-induced reinstatement of nicotine-CPP was significantly blocked in mice pretreated with nor-BNI (F (3,54) 0 10.27, p<0.01). The dose of nor-BNI tested alone had no significant effect on CPP in unstressed mice. There were no significant differences between cohorts on any days tested. CPP locomotor activity counts did not significantly differ between postconditioning reinstatement groups (unstressed/ Sal0483.3±71.6; unstressed/nor-BNI0524.7±107.3; Veh/ FST0492.7±112.3; nor-BNI/FST0508.7±41.3).
Discussion
The primary finding of this study was that the KOR antagonist, nor-BNI, significantly blocked FST stress-induced reinstatement of nicotine-CPP. Exposure to stress via the modified 2-day FST induced a significant CPP in vehicletreated mice, an effect that was blocked by nor-BNI pretreatment. Nor-BNI failed to block nicotine-primed reinstatement of nicotine-CPP, indicating an effect specific to stress-induced mechanisms. These results coincide with a recent study by Smith et al. (2012) , where the FST reinstated nicotine-CPP in saline, but not nor-BNI pretreated mice. Our findings are also consistent with previous reports with cocaine (McLaughlin et al. 2003; Beardsley et al. 2005; Carey et al. 2007; Redila and Chavkin 2008) and ethanol (Sperling et al. 2010) , where stress-induced enhancement of cocaine-and ethanol-induced behaviors was attenuated by selective KOR antagonists. Recently, nor-BNI administered systemically and locally into the amygdala blocked KOR agonist-induced enhancement of nicotine-CPP when administered 1 h prior to testing (Smith et al. 2012) . Similar results were observed with KOR agonists in cocaine-CPP (McLaugh lin et al. 2006) . These results further show that KOR activation plays a significant role in stress-induced reinstatement of drug Fig. 2 Effect of nor-BNI on nicotine-primed reinstatement of nicotine-CPP. Mice conditioned with 0.5 mg/kg nicotine (s.c.) expressed a significant CPP on test day (TD). Significant CPP is present on extinction day 1 (ED1), but is extinguished by day 3 (ED3). On day 8, nicotine-CPP is reinstated by nicotine (RS V/N) (0.1 mg/kg, s.c.) and is not blocked by nor-BNI (RS NB/N) (10 mg/kg, s.c.). Nor-BNI pretreatment had no significant effect on reinstatement of CPP (RS NB/V). Each point represents the mean±SEM of seven to nine mice per group (n05 per group for RS NB/N, n04 per group for RS NB/V). *p <0.05 vs. the corresponding saline group Fig. 3 Effect of nor-BNI on stress-induced reinstatement of CPP. Mice conditioned with 0.5 mg/kg nicotine (s.c.) expressed a robust CPP on test day (TD) and were exposed to the FST to induce stress after three extinction days (ED3). Stress induced a significant reinstatement of nicotine-CPP in vehicle (Veh/FST) pretreated mice, but not in nor-BNI pretreated mice (nor-BNI/FST). A significant CPP was not expressed in vehicle-treated unstressed mice. Nor-BNI had no significant effect on CPP in unstressed mice. Each point represents the mean±SEM of six to eight mice per group. *p<0.05 vs. the corresponding saline/unstressed and nor-BNI-treated groups behaviors. Furthermore, KOR activation in the amygdala induced an anxiety-like response in mice, an effect attenuated by low doses of nicotine (Smith et al. 2012) . Such results also implicate KOR pathways, specifically in the amygdala, in anxiety-like states that lead to drug-seeking behavior.
In addition to mechanisms involved in stress, the kappa opioid system mediates aspects of nicotine dependence. Dynorphin and prodynorphin mRNA levels are altered in the striatum after acute nicotine exposure (Isola et al. 2009 ) and after chronic nicotine exposure and nicotine withdrawal (Isola et al. 2008) . Coinciding with these in vitro studies, both JDTic and nor-BNI attenuate physical and affective nicotine withdrawal signs in mice (Jackson et al. 2010) , suggesting that heightened dynorphinergic tone is involved, in part, in the expression of negative affective states experienced during nicotine withdrawal. Indeed, stress and severity of the nicotine withdrawal syndrome are predictors of smoking relapse (Daughton et al. 1990; West et al. 1989) . Thus, in the case of nicotine, KOR antagonists appear to have the dual effect of blocking multiple contributors to smoking relapse.
Similar to previous findings with cocaine and ethanol, nor-BNI did not block nicotine-primed reinstatement of nicotine-CPP, indicating an effect specific to stress-induced responses and implicating differential mechanisms in stressinduced vs. drug-induced reinstatement of drug relapse. The KOR antagonists JDTic and nor-BNI also had no effect on the expression of nicotine-CPP (Jackson et al. 2010) , and a follow-up study from our lab revealed that JDTic, when administered to mice conditioned with a dose of nicotine that does not produce significant CPP in mice (nicotine, 0.1 mg/kg, s.c.), did not enhance nicotine-CPP (nicotine (0.1)052±10 vs. JDTic (16)−(nicotine (0.1)075±22), suggesting that KORs are not involved in nicotine reward pathways. However, at higher, aversive nicotine doses, nor-BNI pretreatment switched the aversive response to a place preference (Smith et al. 2012) , further supporting a role for the kappa opioid receptor system in mediating aversive effects of nicotine (Jackson et al. 2010) .
In summary, the KOR antagonist nor-BNI blocks stressinduced reinstatement of nicotine-CPP, but not nicotineprimed reinstatement of nicotine-CPP. Taken together with previous studies, the kappa opioid system serves as a potential therapeutic target for suppressing signaling processes associated with multiple aspects of drug abuse maintenance and relapse.
